Semaglutide vs Tirzepatide Dosing Comparison

Semaglutide dosing for weight management typically starts at 0.25 mg weekly and escalates through 0.5 mg, 1.0 mg, and 1.7 mg to a maintenance dose of up to 2.4 mg weekly. The full escalation takes 16 to 20 weeks depending on tolerability.

Tirzepatide starts at 2.5 mg weekly and escalates in 2.5 mg increments through 5 mg, 7.5 mg, 10 mg, and 12.5 mg to a maximum of 15 mg weekly. Dose increases occur every four weeks. The milligram numbers are significantly higher than semaglutide, but this reflects the drug's formulation, not its relative potency per milligram.

Compounded semaglutide is available at 1, 2, 2.5, and 5 mg/mL. At the most common concentration of 5 mg/mL, a 0.25 mg initiation dose is 5 units (0.05 mL) and the 2.4 mg maintenance dose is 48 units (0.48 mL).

Compounded tirzepatide comes in higher concentrations: 5, 10, 20, and 30 mg/mL. At 20 mg/mL, the 2.5 mg initiation dose is 12.5 units (0.125 mL) and the 15 mg maximum dose is 75 units (0.75 mL).

Despite tirzepatide's higher milligram doses, the injection volumes can be comparable to semaglutide because tirzepatide vials use higher concentrations. A patient on semaglutide 1.0 mg from a 5 mg/mL vial injects 20 units, while a patient on tirzepatide 5 mg from a 10 mg/mL vial injects 50 units. Both are comfortable subcutaneous injection volumes.

Semaglutide is a GLP-1 receptor agonist. It mimics the GLP-1 hormone, which reduces appetite, slows gastric emptying, and improves blood sugar control. This single-receptor mechanism has been proven effective in numerous clinical trials.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. In addition to the GLP-1 effects, it also activates GIP receptors, which contribute to improved insulin sensitivity, enhanced fat metabolism, and additional appetite regulation. The dual mechanism is believed to explain why tirzepatide produced greater average weight loss in clinical trials (22.5% vs 14.9% of body weight at the highest doses).

Semaglutide escalation follows a more gradual pattern with smaller incremental increases. The typical schedule is 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance. Some providers modify this timeline based on individual tolerability.

Tirzepatide uses consistent 2.5 mg jumps every 4 weeks: 2.5 mg, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Because the absolute increase is the same at each step, the relative increase gets smaller as the dose goes up. Both medications require patience during escalation. Rushing to higher doses increases gastrointestinal side effects without improving outcomes.

The choice between semaglutide and tirzepatide depends on medical factors including your BMI, health conditions, prior medication history, and treatment goals. Tirzepatide may be recommended for patients with higher BMIs or those who need more aggressive weight loss. Semaglutide has a longer track record and more extensive cardiovascular outcome data.

From a dosing perspective, both medications use the same syringe type (U-100 insulin) and the same injection technique (subcutaneous, once weekly). The conversion formula is identical: units = (dose in mg / concentration in mg per mL) x 100. Your provider will determine the medication, dose, and concentration. Always consult your healthcare provider to determine which medication is appropriate for your specific situation.